Location: Cambridge, Mass.

R&D Focus: Using a CRISPR-based discovery platform to identify new drug targets and develop novel, targeted therapies

Disease Areas: Oncology and immunology

Founding Date: 2015

Founders: David Sabatini, Whitehead Institute for Biomedical Research and MIT; William Hahn, Broad Institute and Dana-Farber Cancer Institute; Jonathan Weissman, UCSF; and Tim Wang, MIT. Founding investors were Flagship Pioneering and Polaris Partners.

Employees: 40

Financing To Date: $76m

Investors: Flagship and Polaris funded the company's Series A and recent Series B round, the latter of which was led by Flagship and included Polaris, ARCH Venture Partners and Alexandria Equities.

KSQ Comes Out Of Stealth Mode With $76m And Meeker As CEO

More from Start-Ups & SMEs

More from Business